Molecular Partners AG American Depositary Shares (MOLN)
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript
Molecular Partners AG ( MOLN ) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program November 12, 2025 10:00 AM EST Company Participants Patrick Amstutz - Co-Founder, CEO, Member of Management Board & Director Daniel Steiner - Senior Vice President of Research & Technology Philippe Legenne - Chief Medical Officer & Member of the Management Board Michael Stumpp - Co-Founder, Executive VP of Projects & Member of Management Board Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the MP0712 update call.
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Molecular Partners AG Sponsored ADR (MOLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript
Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe Legenne - Chief Medical Officer Robert Hendriks - SVP Finance Seth Lewis - SVP Investor Relations, Communications and Strategy Conference Call Participants Jonathan Chang - Leerink Partners Richard Vosser - JPMorgan Michael Nedelcovych - TD Cowen Joris Zimmermann - Octavian Operator Good morning, and welcome to the Molecular Partners Fourth Quarter and Full Year 2024 Results Call. All participants will be in listen-only mode.
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
The consensus price target hints at an 80.7% upside potential for Molecular Partners AG Sponsored ADR (MOLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
